INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial

Autor Patt, Yehuda Z., Murad, Waheed, Fekrazad, Mohammed H., Baron, Ari D., Bansal, Pranshu, Boumber, Yanis, Steinberg, Kim, Lee, Sang‐Joon, Bedrick, Ed, Du, Ruofei, Lee, Fa Chyi
Vydáno v Cancer Med (2017)

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

Autor Danila, Daniel C., Szmulewitz, Russell Z., Vaishampayan, Ulka, Higano, Celestia S., Baron, Ari D., Gilbert, Houston N., Brunstein, Flavia, Milojic-Blair, Marija, Wang, Bei, Kabbarah, Omar, Mamounas, Michael, Fine, Bernard M., Maslyar, Daniel J., Ungewickell, Alexander, Scher, Howard I.
Vydáno v J Clin Oncol (2019)

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Autor Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, Afsaneh, Guthrie, Katherine A., Javle, Milind, Hochster, Howard
Vydáno v Eur J Cancer (2020)

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

Autor Ross, Helen J., Hart, Lowell L., Swanson, Paul M., Rarick, Mark U., Figlin, Robert A., Jacobs, Andrew D., McCune, David E., Rosenberg, Arthur H., Baron, Ari D., Grove, Laurie E., Thorn, Michael D., Miller, Dennis M., Drachman, Jonathan G., Rudin, Charles M.
Vydáno 2006

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Autor Finn, Richard S., Ikeda, Masafumi, Zhu, Andrew X., Sung, Max W., Baron, Ari D., Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E., Saito, Kenichi, Siegel, Abby B., Dubrovsky, Leonid, Mody, Kalgi, Llovet, Josep M.
Vydáno v J Clin Oncol (2020)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Autor Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K
Vydáno v ESMO Open (2020)